(HealthDay News) — For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is ...
Please provide your email address to receive an email when new articles are posted on . Reduced dosing of direct oral anticoagulants for VTE conferred comparable efficacy as full dosing. Reduced ...
Eliquis Offered to Cash-Paying Patients at More Than 40% Discount to Current List Price, Sotyktu at More Than 80% Discount to Current List Price PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb ...
Apixaban may be safer and more effective than rivaroxaban for treating nonvalvular atrial fibrillation (AF), a new observational study suggests. The study, one of the largest to compare the two drugs ...
MADRID -- Extended low-dose apixaban (Eliquis) after venous thromboembolism (VTE) provoked by events like trauma or surgery in patients with obesity or other enduring risk factors dramatically reduced ...
Very elderly people with nonvalvular atrial fibrillation (Afib) got the same stroke prevention benefits from edoxaban (Savaysa) and apixaban (Eliquis), though one drug was associated with more major ...
Among patients hospitalized for atrial fibrillation (AF) or flutter, prescription of an off-label dose of a direct oral anticoagulant (DOAC) at discharge remains relatively common, according to data ...
Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot ...
The efficacy and safety of apixaban for VTE prophylaxis in major orthopedic surgery have been evaluated in one Phase II trial and three Phase III trials. Traditional treatment of acute VTE entails ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results